ArticleNeoplasia (New York, N.Y.)2017

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.

Stuart W Hicks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.